Business Wire

GOTO

15.3.2022 05:30:10 CET | Business Wire | Press release

Share
GoTo Announces Initial Public Offering on Indonesia Stock Exchange

PT GoTo Gojek Tokopedia Tbk (“GoTo Group” or the “Group”), the largest digital ecosystem in Indonesia, today announced its plan to carry out an initial public offering (the “IPO”) on the Indonesia Stock Exchange (IDX). The IPO is expected to raise proceeds of at least IDR 15.2 trillion (USD1.1 billion) and will be one of the most significant ever conducted in the country.

Andre Soelistyo, GoTo Group CEO said , “This is a landmark moment in the history of our company as we set out on the final stretch towards becoming a publicly owned company on the Indonesia Stock Exchange. Indonesia is one of the largest and most exciting growth markets in the world, as reflected in the resilience our capital market has shown this year, against a backdrop of global market volatility. We hope that our IPO will show the world the tremendous opportunity that exists in our country and throughout the Southeast Asia region.”

“The strength of our business is that we are more than the sum of our parts. Our ecosystem of on-demand, e-commerce and financial technology services connects millions of consumers, driver-partners and merchants, with the mission to empower progress for everyone in the fast-growing digital economy. We are proud that we’ve come from humble origins in Indonesia, earned the trust of millions of consumers, driver-partners, and merchants, partnered with leading global investors and are now taking our next steps in building an iconic, internationally renowned technology company.”

“I would like to express our gratitude to the Government of Indonesia for creating an environment that is enabling home-grown tech companies like ours to thrive and for supporting the nation’s digital transformation, which will ultimately benefit everyone.”

GoTo Group is a unique ecosystem that combines on-demand, e-commerce, and financial services through the Gojek, Tokopedia, GoTo Financial platforms. The integration of the three businesses under a single ecosystem brings significant synergies including a hyperlocal delivery network, cross-platform consumer loyalty capabilities and a broad financial services offering across multiple use cases. The breadth and ubiquity of the Group and its businesses are such that the ecosystem contributes to more than 2% of Indonesia’s GDP1 and its services address nearly two-thirds2 of the country’s household consumption.

As part of the IPO, and in-line with its ongoing commitment to delivering a positive social impact, GoTo Group is also planning to launch the Gotong Royong Share Program3 , which will provide the Group’s most active, long-serving and loyal driver-partners, merchants and consumers, as well as employees, with the opportunity to benefit from the IPO. Under the program, all full time employees4 have been made participants in the Group’s Long-Term Incentive Plan Program, long-serving driver-partners are set to receive grants, while the most loyal merchants and GoTo Group consumers will be eligible to purchase shares via a fixed allocation at IPO.

Andre added , “Our listing will be a great moment for those involved in the success of our ecosystem and for everyone that believes in the ‘Indonesian dream’. That is why it was important for us to provide the driver-partners, merchants, consumers and employees in our ecosystem with the opportunity to benefit from the IPO through this highly inclusive and globally unique share program.”

Indonesia’s tech champion

GoTo Group is the market leader in Indonesia in each of its business verticals and with the advantage of synergies and network effects from within its large ecosystem, the Group is well positioned to capture market growth and has achieved:

  • Pro forma5 Gross Transaction Value (GTV) of IDR414.2 trillion (USD28.8 billion) in the 12-months ended 30 September 2021
  • Pro forma Gross Revenue of IDR15.1 trillion (USD1 billion) in the 12-months ended 30 September 2021
  • Pro forma Orders of approximately 2 billion in in the 12-months ended 30 September 2021
  • Over 55 million annual transacting users (ATU) on a pro forma basis, as of 30 September, 2021
  • Over 2.5 million registered driver partners, as of 30 September, 2021
  • Over 14 million registered merchants, as of 30 September, 2021

GoTo Group’s total addressable market (TAM)6 in Indonesia is expected to grow significantly by 2025.

  • On-demand services TAM is expected to grow from approximately USD5.4 billion in 2020 to approximately USD18 billion in 2025;
  • E-commerce TAM for physical goods is expected to grow from approximately USD44.6 billion in 2020 to approximately USD137.5 billion in 2025;
  • Financial technology services TAM is expected to grow from approximately USD17.8 billion in 2020 to approximately USD70.1 billion in 2025.

Indonesia is the region’s largest economy, contributing a GDP of more than USD1 trillion and a population of 274 million, making it the largest country in Southeast Asia and the fourth largest in the world. Indonesia and Southeast Asia have a young and highly tech-savvy population with growing spending power that is driving the growth of the region’s digital economy.

Growing demand for services across GoTo Group’s ecosystem, driven by increasing digital adoption among consumers in Southeast Asia, has underpinned the Group’s strong financial performance. GoTo Group’s pro forma GTV grew at 46% CAGR between 2018 and 2020, and at 62% YoY between Q3 2020 and Q3 2021. Pro forma gross revenue grew at 56% CAGR between FY2018 and FY2020 and 55% YoY between Q3 2020 and Q3 2021.

A landmark transaction for GoTo Group and for the Indonesian Stock Exchange

The listing will be the first to be carried out under the new regulations on multiple voting shares set out by the OJK, as well as the new listings regulations set out by the IDX. The company intends to offer 48 billion Series A shares (which may be upsized to a maximum of 52 billion Series A shares), consisting entirely of new shares issued by the Company and representing up to 4.35% of its enlarged capital upon completion of the IPO (excluding any over-allotment shares). As such, the company expects to raise at least IDR 15.2 trillion (USD1.1 billion) plus an additional IDR 2.3 trillion (USD160 million) should the greenshoe option be exercised.

The price range for the IPO has been set at IDR 316-346 per share, implying an estimated market capitalisation at admission to the IDX of between IDR 376.6 trillion (USD26.2 billion) and IDR 413.7 trillion (USD28.8 billion).

GoTo Group plans to use the proceeds from the IPO, after deducting issuance costs, for working capital to support the Group’s growth strategy. An initial offer (book building) will be executed between March 15-21, 2022, with a public offering period targeted for March 29-31 2022. Listing on the Main Board of the IDX with the stock code GOTO will take place over the coming weeks.

GoTo Group has appointed PT Indo Premier Sekuritas, PT Mandiri Sekuritas, and PT Trimegah Sekuritas Indonesia Tbk as the Joint Lead Underwriters for the IPO. The details of the IPO were announced during a Public Expose event that took place today, March 15, 2022.

Notes to editors:

For more information on GoTo and the IPO, please see the Prospectus at gotocompany.com .

Definition of pro-forma : The pro forma information of GTV, Orders, ATU and gross revenue provided is as if Tokopedia had been consolidated by GoTo since January 1, 2018.

Exchange rate: IDR14.400 = USD1

About GoTo Group:

PT GoTo Gojek Tokopedia Tbk (GoTo Group) is the largest digital ecosystem in Indonesia. GoTo's mission is to "empower progress" by offering technology infrastructure and solutions that help everyone to access and thrive in the digital economy. The GoTo ecosystem consists of on-demand services (mobility, food delivery, and logistics), e-commerce (third party marketplaces + official stores, instant commerce, interactive commerce, and rural commerce), and financial technology (payments, financial services, and technology solutions for merchants) through the Gojek, Tokopedia, and GoTo Financial platforms.

______________________________________

1 Based on GoTo 2020 pro forma GTV as a percentage of Indonesia’s 2020 GDP, as per Euromonitor
2 Data provided by RedSeer
3 The implementation of the program will be subject to the issuance of effective statement by Financial Services Authority of Indonesia
4 As of November 2021
5 See notes to editors for pro forma definition.
6 Data for on-demand, e-commerce, and e-wallet market sizes provided by RedSeer

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye